tradingkey.logo
tradingkey.logo
Search

Castle Biosciences Inc

CSTL
Add to Watchlist
24.110USD
-0.600-2.43%
Close 07/02, 13:00ETQuotes delayed by 15 min
731.26MMarket Cap
LossP/E TTM

More Details of Castle Biosciences Inc Company

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

Castle Biosciences Inc Info

Ticker SymbolCSTL
Company nameCastle Biosciences Inc
IPO dateJul 25, 2019
CEOMaetzold (Derek J)
Number of employees761
Security typeOrdinary Share
Fiscal year-endJul 25
Address505 S Friendswood Drive
CityFRIENDSWOOD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77546
Phone18667889007
Websitehttps://castlebiosciences.com/
Ticker SymbolCSTL
IPO dateJul 25, 2019
CEOMaetzold (Derek J)

Company Executives of Castle Biosciences Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
127.71K
-6.72%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
98.03K
+11.43%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
35.63K
+38.36%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
33.00K
+41.42%
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Frank Stokes
Mr. Frank Stokes
Chief Financial Officer
Chief Financial Officer
--
--
Mr. G. Bradley Cole
Mr. G. Bradley Cole
Independent Director
Independent Director
--
--
Ms. Kimberlee S. Caple
Ms. Kimberlee S. Caple
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
127.71K
-6.72%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
98.03K
+11.43%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
35.63K
+38.36%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
33.00K
+41.42%

FAQs

Who are the top five shareholders of Castle Biosciences Inc?

The top five shareholders of Castle Biosciences Inc are: Mr. Derek J. Maetzold

How many institutions hold shares of Castle Biosciences Inc (CSTL)?

As of 2026Q1, 413 institutions hold shares of Castle Biosciences Inc, with a combined market value of approximately 27.62M, accounting for 91.06% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -1802863.00.